From the Department of General Surgery, Necmettin Erbakan University Meram Faculty of Medicine, Konya, Turkey.
Pancreas. 2022 Feb 1;51(2):159-163. doi: 10.1097/MPA.0000000000001981.
Gastorenteropancreatic neuroendocrine (GEP-NET) tumors are the second most common tumors of the gastrointestinal tract. We aimed to investigate the clinicopathological features and factors affecting the prognosis of patients with GEP-NET.
Clinicopathological features of 158 patients were evaluated, including tumor location, TNM stage and grade, pathological features, presence of lymph nodes and distant metastases at the time of diagnosis, maximum tumor diameter and treatment details. Also, follow-up information was analyzed to discover possible prognostic factors.
The most common primary site is pancreas (45.6%, n = 72). Most of the GEP-NETs were nonfunctional (93.6%, n = 148). Of the 158 patients, 94 (59.5%) were grade 1, 46 (29.1%) grade 2, and 18 (11.4%) grade 3. The 1-year, 3-year, and 5-year survival rates were 82.3% (130/158), 61.4% (70/114), and 47.2% (35/74), respectively. In multivariate analysis, histological grade (P = 0.04) and TNM stage (P < 0.001) were independent prognostic factors for survival in patients with GEP-NET.
They are increasing in frequency and are the most common tumors in the pancreas. Nonfunctional tumors made up the majority of cases. The main treatment was surgical resection. Histological grade and TNM stage are independent prognostic factors.
胃胰肠神经内分泌肿瘤(GEP-NET)是胃肠道第二常见的肿瘤。本研究旨在探讨 GEP-NET 患者的临床病理特征及影响预后的因素。
评估了 158 例患者的临床病理特征,包括肿瘤部位、TNM 分期和分级、病理特征、诊断时淋巴结和远处转移的存在情况、最大肿瘤直径和治疗细节。还分析了随访信息,以发现可能的预后因素。
最常见的原发部位是胰腺(45.6%,n=72)。大多数 GEP-NET 为无功能性(93.6%,n=148)。在 158 例患者中,94 例(59.5%)为 1 级,46 例(29.1%)为 2 级,18 例(11.4%)为 3 级。患者的 1 年、3 年和 5 年生存率分别为 82.3%(130/158)、61.4%(70/114)和 47.2%(35/74)。多因素分析显示,组织学分级(P=0.04)和 TNM 分期(P<0.001)是影响 GEP-NET 患者生存的独立预后因素。
GEP-NET 的发病率呈上升趋势,是胰腺最常见的肿瘤。无功能性肿瘤占多数。主要治疗方法是手术切除。组织学分级和 TNM 分期是独立的预后因素。